@dansfera: Mark your calendars for July 17th. All eyes are on CELC as the FDA prepares to drop a decision on Gidatoslib, a potential new breakthrough for patients battling advanced breast cancer. Specifically targeting hormone-positive AGR2—the most common form that has progressed beyond first-line treatment—this drug is moving through a priority, real-time oncology review. It’s a fast-tracked development that demands attention for anyone tracking the intersection of biotech innovation and oncology. #biotech #breastcancer #FDAdecision #CELC #investinginsights

dansfera

Open In TikTok:

Region: US

Wednesday 29 July 2026 22:19:22 GMT